JOHN HEYMACH, MD, PhD

Dr. Heymach received his MD and PhD from Stanford University. He completed his residency at Brigham and Women’s Hospital and his fellowship in medical oncology through the Dana-Farber/ Mass General Brigham program. At the University of Texas MD Anderson Cancer Center, Dr. Heymach is the Chair of Thoracic/Head and Neck Medical Oncology and holds the David Bruton Endowed Chair in Cancer Research. His research focuses on understanding mechanisms of targeted therapy resistance, elucidating the role of angiogenesis regulation in lung cancer, and biomarker development for precision therapy in lung cancer patients. His research has led to new therapeutic approaches for KRAS-mutant lung cancer, small cell lung cancer, EGFR-mutant non-small cell lung cancer, adenoid cystic carcinoma, and oligometastatic non-small cell lung cancer, many of which are now considered standard of care regimens or undergoing clinical testing. Dr. Heymach serves as a co-principal investigator and project leader on the UT Lung Cancer SPORE and is the principal investigator on four NCI R01 awards investigating molecular subsets of lung cancer and on a U01 focused on small cell lung cancer. He serves as the MDACC principal investigator for the SU2C-ACS Lung Cancer Dream Team targeting KRAS-mutant lung cancers, as the leader of the Lung CCSG Program, and the co-leader of the Lung Cancer Moon Shot.